The necessity to adhere to evidence-based indications for hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with ovarian cancer

Brennan, Donal J.; Driel, Willemien J. van; Zivanovic, Oliver

doi:10.1136/ijgc-2023-004411

Cited by 3 publications

(5 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…25 However, criticisms that the study analysis changed during the trial, of histological imbalance between the two groups and with regard to surgical experience have since been refuted. 25,26 A further randomised controlled trial (RCT) conducted in Korea has now shown similar results to the van Driel study. 27 The study protocol was cisplatin 75 mg/m 2 at 41.5°C for 90 minutes.…”

Section: Interval Surgerymentioning

confidence: 85%

“…Despite the encouraging published results, HIPEC use remains contentious. 26 Critics of HIPEC point to its ineffectiveness against retroperitoneal or extra-abdominal tumour where tumour burden may also be significant. 35 They also suggest limitations to the mode of action, particularly regarding depth of drug penetration, and that the high concentration at peritoneal surfaces can be achieved by provision of high-dose intravenous chemotherapy.…”

Section: Limitations Of Hipecmentioning

confidence: 99%

“…However, criticisms that the study analysis changed during the trial, of histological imbalance between the two groups and with regard to surgical experience have since been refuted 25,26 …”

Section: Current Evidence For Hipecmentioning

confidence: 99%

“…Despite the encouraging published results, HIPEC use remains contentious 26 . Critics of HIPEC point to its ineffectiveness against retroperitoneal or extra‐abdominal tumour where tumour burden may also be significant 35 .…”

Section: Limitations Of Hipecmentioning

confidence: 99%

See 3 more Smart Citations

Hyperthermic intraperitoneal chemotherapy (HIPEC) in the management of ovarian cancer

Graham,

MacDonald,

Mould

et al. 2024

The Obstetric & Gynaecologis

View full text Add to dashboard Cite

Key content Hyperthermic intraperitoneal chemotherapy (HIPEC) at the time of cytoreductive surgery is a proposed additional treatment in the management of advanced tubo‐ovarian cancer. Additional organisational approvals, costs, changes to theatre infrastructure and pre‐, intra‐, and post‐operative management considerations are required to implement HIPEC in a clinical setting. Current meta‐analysis data suggest that in the setting of interval cytoreductive surgery, HIPEC prolongs overall survival and progression‐free survival. There is currently no evidence of benefit in the setting of primary surgery or recurrent disease, but results of ongoing clinical trials are pending. Learning objectives To understand the mechanism of action, safety and efficacy of HIPEC as an adjuvant treatment in tubo‐ovarian cancer. Ethical issues Because of variation in treatment protocols and heterogeneity of reported outcomes, HIPEC has not yet been adopted into standard practice. Further studies assessing its benefit, mainly in the setting of primary cytoreduction, are ongoing.

show abstract

Section: Interval Surgerymentioning

confidence: 85%

Section: Limitations Of Hipecmentioning

confidence: 99%

Section: Current Evidence For Hipecmentioning

confidence: 99%

Section: Limitations Of Hipecmentioning

confidence: 99%

See 2 more Smart Citations

Hyperthermic intraperitoneal chemotherapy (HIPEC) in the management of ovarian cancer

Graham,

MacDonald,

Mould

et al. 2024

The Obstetric & Gynaecologis

View full text Add to dashboard Cite

show abstract

“…Patient selection and procedure specifics are crucial for HIPEC’s effectiveness, necessitating further research for standardization [ 14 ]. Current data support the use of HIPEC only after optimal interval cytoreductive surgery in advanced stages, emphasizing the need for strict adherence to evidence-based guidelines and more research to refine these recommendations [ 15 ].…”

Section: Introductionmentioning

confidence: 99%

Exploring the Survival Determinants in Recurrent Ovarian Cancer: The Role of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy

Gęca,

Litwiński,

Ostrowski

et al. 2024

Cancers

View full text Add to dashboard Cite

Background: Recurrent ovarian cancer (ROC) significantly challenges gynecological oncology due to its poor outcomes. This study assesses the impact of cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) on ROC survival rates. Materials and Methods: Conducted at the Medical University of Lublin from April 2011 to November 2022, this retrospective observational study involved 71 patients with histologically confirmed ROC who underwent CRS and subsequent HIPEC. Results: The median overall survival (OS) was 41.1 months, with 3-year and 5-year survival rates post-treatment of 0.50 and 0.33, respectively. Patients undergoing radical surgery for primary ovarian cancer had a median OS of 61.9 months. The key survival-related factors included the Peritoneal Carcinomatosis Index (PCI) score, AGO score, platinum sensitivity, and ECOG status. Conclusions: The key factors enhancing ROC patients’ survival include radical surgery, optimal performance status, platinum sensitivity, a positive AGO score, and a lower PCI. This study highlights the predictive value of the platinum resistance and AGO score in patient outcomes, underlining their role in treatment planning. Further prospective research is needed to confirm these results and improve patient selection for this treatment approach.

show abstract

The 2022 PSOGI International Consensus on HIPEC Regimens for Peritoneal Malignancies: Epithelial Ovarian Cancer

Bhatt¹,

Gléhen

Zivanovic

et al. 2023

Ann Surg Oncol

View full text Add to dashboard Cite

The necessity to adhere to evidence-based indications for hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with ovarian cancer

Cited by 3 publications

References 5 publications

Hyperthermic intraperitoneal chemotherapy (HIPEC) in the management of ovarian cancer

Hyperthermic intraperitoneal chemotherapy (HIPEC) in the management of ovarian cancer

Exploring the Survival Determinants in Recurrent Ovarian Cancer: The Role of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy

The 2022 PSOGI International Consensus on HIPEC Regimens for Peritoneal Malignancies: Epithelial Ovarian Cancer

Contact Info

Product

Resources

About